Chemokine achieves positive results with cancer treatment

The preliminary results of the Phase I/II trial demonstrated that CTCE-9908 is well tolerated with no dose limiting toxicity observed up to the maximum dose of 5mg/kg/day that was tested. The main side effect at the maximum dose tested was moderate phlebitis (blood vessel inflammation). The preliminary results found that seven out of twenty cancer patients showed stable disease after one month and one patient with small bowel carcinoma showed stable disease after six months of therapy with CTCE-9908.

The company is continuing with its plans to start an international Phase II study in 2008.